PDSB Stock Forecast & Price Target

PDS Biotechnology is a clinical stage biotechnology company that has recently redirected its focus and resources towards PDS0301, its tumor-targeted IL-12 immunocytokine, for the treatment of difficult-to-treat cancers, particularly metastatic colorectal cancer with liver metastases. This decision was based on encouraging clinical data and potential applicability across a broader range of solid tumors. Despite a crowded field, PDS Biotechnology's PDS0101 retains several points of differentiation, including a more convenient administration and strong survival data compared to competitors. While there are still risks involved, the planned Phase 2b study in a larger patient population will help address current data limitations and determine the potential of PDS0301 without the need for a surgically implanted hepatic artery pump. Overall, we maintain a Buy rating with a price target of $5 based on our clinical net present value (NPV) model driven by PDS0301 and PDS0101.

PDS Biotechnology is in a precarious financial position, as evidenced by the recent 36% reduction of its workforce and need for external funding to advance its lead product PDS0301. The decision to prioritize PDS0301 and seek a commercial partner for PDS0101 reflects the company's limited resources and the challenges of competitively launching a Phase 3 program in the increasingly crowded HNSCC market. While the survival data for PDS0301 is encouraging, financing and dilution risk remain central to the investment case, and the company's valuation may be conservative due to its lack of value placed on potential indications beyond colorectal cancer.